舒血宁注射液联合复合辅酶治疗慢性移植肾肾病43例

摘要

目的 观察舒血宁注射液联合复合辅酶治疗慢性移植肾肾病 (CAN) 的临床疗效.方法回顾性分析我院2014年6月至2018年5月肾移植科收治的108例CAN的患者, 按照治疗方法的不同分为两组.其中试验组为舒血宁注射液联合复合辅酶43例, 对照组非舒血宁+复合辅酶65例.两组均维持原免疫方案不变, 治疗4周后, 总结观察移植肾治疗前后的血流动力学参数的变化、临床疗效、生化指标、凝血功能及不良反应.结果 治疗前两组患者的基线资料差异无统计学意义 (P>0.05) .治疗后, 试验组的段间动脉和皮质小动脉的收缩期峰值流速明显高于对照组 (P 0.05) .治疗后, 试验组血小板计数、纤维蛋白原、D二聚体较治疗前显著降低 (P 0.05). After treatment, the peak systolic velocity of the intersegmental artery and cortical arteriole in the experimental group were significantly higher than that the control group (P 0.05). After treatment, the platelet count, fibrinogen and D-dimer of the experimental group were significantly lower than those before treatment (P < 0.05) , and the activated partial thrombin time (APT) was significantly higher than that before treatment (P < 0.05). Significant difference in platelet count, fibrinogen, D-dimer and APTT was found after treatment (P < 0.05). After 4 weeks of treatment, the values of urea nitrogen and serum creatinine were significantly lower than those of the control group (P < 0.05). The recovery of transplanted kidney function in the experimental group was higher than that in the control group (P < 0.05). The experimental group reported 2 cases of fatigue complain and 1 case of dizziness, but no special treatment was given to them and their condition improved after symptomatic treatment; 1 case of mild phlebitis which was cured after given slowed drip rate and local hot compress therapy. The incidence of adverse events was 9.3％ (4/43). The control group reported 2 cases of fatigue complain, 1 case of nausea, 1 case of facial flushing, and all cured with no special treatment was given; 1 case of mild phlebitis, and cured after slowed the i.v. drip rate and ocal hot compress; The adverse events rate was 7.7％ (5/65). No serious adverse reactions occurred during the entire clinical trial. There was no significant difference in the incidence of adverse events between the experimental group and the control group (χ2=0.054, P=0.732). Conclusion Combined with Shuxuening injection and compound coenzyme can improve blood flow of transplanted kidney, reduce proteinuria, reduce blood urea nitrogen and creatinine in patients with CAN after renal transplantation and effectively improve patient's hemodynamic parameters and safety.